On Friday, Medtronic plc (NYSE:MDT) released results from the SPHERE Per-AF study comparing Sphere-9 to the conventional Thermocool SmartTouch SF radiofrequency ablation catheter with the Carto 3 System. The findings were presented as late-breaking clinical data at the Heart Rhythm Society 2024 Annual Meeting and published in Nature Medicine.   The study demonstrated the safety and efficacy of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high-density (HD) mapping catheter for persistent atrial fibrillation (AFib).  Atrial fibrillation (AFib) is a quivering ...